# Monogram mBos: Price, Availability & Status (2026)

Monogram's mBos is the autonomy-boundary surgical robot: the cleared system is semi-autonomous (the robot cuts under AI control + surgeon supervision), not surgeon-controlled. Pre-commercial, no price.

## Price

_No verified price on record._

There is no consumer price. The mBos is pre-commercial enterprise surgical equipment that has not sold any units; DEPLOY records zero price points.

## Availability

_Status: internal-only_

The mBos is enterprise surgical equipment, not a consumer product, and it is pre-commercial: zero units sold. From Monogram Technologies (a Zimmer Biomet subsidiary since October 2025), commercialization alongside Zimmer Biomet implants is targeted for early 2027.

## Status

The Monogram mBos TKA System is a robotic total-knee-arthroplasty platform and the autonomy-boundary case of DEPLOY's surgical cluster. Unlike the AI-augmented, surgeon-controlled systems (Stryker Mako, Smith+Nephew CORI, Zimmer Biomet ROSA), where the surgeon makes the cuts, the cleared mBos is semi-autonomous: a robotic arm (built on a KUKA arm) executes the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. It pairs CT-based planning and predictive navigation with the robotic arm to execute cutting and insertion paths for Monogram's mPress press-fit implants. Several verified-vs-claimed cap-flags apply. It received FDA 510(k) clearance on March 17, 2025, but the exact K-number could not be independently verified, and the 'semi-autonomous' characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter (Monogram's own clearance release described it more softly as robotic-assisted TKA). A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development (targeted around late 2027 or 2028); its first live-patient procedure (July 26, 2025, Ahmedabad, India) was under an India CDSCO 102-procedure investigation, not US FDA, a single index case with no verified peer-reviewed outcomes.

## Compare

| Model | Pricing | Tier |
| --- | --- | --- |
| [Zimmer Biomet ROSA](/price/zimmer-biomet-rosa) | No consumer price | absence (Surgeon-controlled (same parent: ZB)) |
| [Stryker Mako](/price/stryker-mako) | No consumer price | absence (AI-augmented (surgeon-controlled)) |
| [Smith+Nephew CORI](/price/smith-nephew-cori) | No consumer price | absence (AI-augmented (handheld knee)) |
| [Intuitive da Vinci](/price/intuitive-da-vinci) | No consumer price | absence (Production (general laparoscopy)) |

## Common questions

### Can I buy a Monogram mBos?

No. The mBos is pre-commercial enterprise surgical equipment that has not sold any units; there is no consumer price.

### Is the Monogram mBos autonomous?

The cleared mBos is semi-autonomous: the robotic arm executes the bone cuts under AI control within a surgeon-approved CT plan and active surgeon supervision (the robot cuts, the surgeon supervises). A separate fully-autonomous, hands-free version is NOT FDA cleared and remains in development.

## How DEPLOY verified this

- [How DEPLOY tracks pricing](https://news.deploy.report/methodology/how-we-track-pricing)
- [How DEPLOY verifies deployment status](https://news.deploy.report/methodology/how-we-verify-deployment-status)

## Related reading

- [Deploy News: What is the Monogram mBos?](https://news.deploy.report/explainers/what-is-monogram-mbos)
- [Deploy News: Surgical robotics](https://news.deploy.report/explainers/surgical-robotics)
- [Deploy News: How DEPLOY verifies](https://news.deploy.report/explainers/how-deploy-verifies)

## On the registry

- [Model record](https://registry.deploy.report/models/monogram-mbos.md)
- [Manufacturer](https://registry.deploy.report/companies/monogram.md)

_Canonical: https://deploy.report/price/monogram-mbos_